Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
-$0.04 today
- Market cap
- $694.94M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
Volume 4.62M
Average 2.47M
PRME Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Prime Medicine, Inc.NASDAQ: PRME
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $1.86M rose 20.8% year over year, ahead of the -10.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 261.1% from the prior quarter. Over 3 fiscal years it compounded at +34.3% a year.
Context
- Depreciation & amortization amounted to 116.2% of revenue in FY2025, down 89.2 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +20.8% holds above the trailing-twelve-month pace of -10.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 5.38M USD
- Year-over-year change
- -12.1%
- 4-year CAGR
- +75.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.38M | -12.1% |
| FY2024 | 2024-12-31 | 6.13M | +31.7% |
| FY2023 | 2023-12-31 | 4.65M | +109.2% |
| FY2022 | 2022-12-31 | 2.22M | +291.5% |
| FY2021 | 2021-12-31 | 568K | — |
Depreciation & Amortization vs competitors
How PRME compares with its peers on the latest reported figures
- PRME's LTM Mar 2026 depreciation & amortization of $5.7M is the 4th largest of the 7 companies compared; the peer median is $7.08M.
- Its year-over-year change of -10.2% is the 5th highest of 7, against a peer median of -1.8%.
- Depreciation & amortization amounts to 141.4% of revenue for PRME, versus a peer median of 15.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $22.24M | +1.2% | +16.4% | 14.3% | |
| LTM Sep 2026 | $18.5M | -0.9% | -6.9% | 73.5% | |
| LTM Mar 2026 | $9.99M | -2.7% | +10.7% | 15.1% | |
| LTM Mar 2026 | $5.7M | -10.2% | +34.3% | 141.4% | |
| LTM Mar 2026 | $4.17M | -34.0% | -5.9% | 10.8% | |
| LTM Mar 2026 | $3.13M | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $1.02M | +66.8% | — | — | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding PRME) | $7.08M | -1.8% | +0.0% | 15.1% | |
Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (165.37M) | (121.82M) | (198.13M) | (195.88M) | (201.14M) |
| Depreciation & Amortization | 568K | 2.22M | 4.65M | 6.13M | 5.38M |
| Deferred Income Tax | (624K) | (964K) | (279K) | 0 | 0 |
| Stock-Based Compensation | 1.75M | 6.46M | 13.91M | 26.07M | 29.27M |
| Change in Working Capital | 31.18M | (35.4M) | 2.65M | 31.08M | (5.34M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.19M | 2.46M | 9.14M | (5.26M) | 996K |
| Other Working Capital | 29.99M | (37.86M) | (6.49M) | 36.33M | (6.34M) |
| Other Non-Cash Items | 98.42M | 17.68M | 11.79M | 9.75M | 9.27M |
| Operating Cash Flow | (34.08M) | (131.83M) | (165.41M) | (122.87M) | (162.56M) |
| Capital Expenditures | (4.15M) | (16.1M) | (8.72M) | (7.29M) | (4.53M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (81.98M) | (123.34M) | (104.95M) | (129.45M) | (205.41M) |
| Sales of Investments | 13M | 93M | 132.56M | 204.2M | 101.18M |
| Other Investing Activities | (496K) | (665K) | (170K) | 1M | 0 |
| Investing Cash Flow | (73.63M) | (47.1M) | 18.71M | 68.46M | (108.76M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 270.36M | 185.32M | 655K | 170.14M | 139.51M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.09M) | (3.82M) | 0 | 25.74M | 12M |
| Financing Cash Flow | 269.28M | 181.49M | 655K | 195.88M | 151.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 161.57M | 2.57M | (146.05M) | 141.47M | (119.82M) |
| Free Cash Flow | (38.23M) | (147.92M) | (174.14M) | (130.16M) | (167.1M) |
Prime Medicine, Inc.
NASDAQ:PRME
Intrinsic Alpha fair value
Locked
Current Price
$3.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.